Advanced Catheter Therapies (ACT) is an early-stage research and development medical device company founded to address vascular diseases such as thrombosis, inflammation, occlusions, and restenosis. The company's core mission is to develop innovative catheter technologies that improve the treatment and prevention of these conditions. ACT's flagship product, the Pressana Occlusion Perfusion Catheter (OPC), creates a localized treatment chamber for the targeted delivery of therapeutic agents, offering substantial procedural control for physicians.

Notable affiliated individuals and investors include key figures in the medical device industry who have supported ACT's vision. The company has achieved significant milestones, including the development and market availability of the Pressana OPC, which has been recognized for its potential to revolutionize vascular disease treatment. ACT's impact lies in its commitment to advancing medical technology and improving patient outcomes through innovative solutions for vascular health.